Država: Kanada
Jezik: angleščina
Source: Health Canada
CHOLESTYRAMINE RESIN
JAMP PHARMA CORPORATION
C10AC01
COLESTYRAMINE
4G
POWDER FOR SUSPENSION
CHOLESTYRAMINE RESIN 4G
ORAL
100
Prescription
BILE ACID SEQUESTRANTS
Active ingredient group (AIG) number: 0101047008; AHFS:
APPROVED
2019-11-29
JAMP-Cholestyramine (Cholestyramine for Oral Suspension, USP) Page 1 of 27 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR JAMP-CHOLESTYRAMINE Cholestyramine for Oral Suspension, USP Light Powder, 4 g Cholestyramine Resin / Dose Regular Powder, 4 g Cholestyramine Resin / Dose Antihypercholesterolemic and Antidiarrheal JAMP Pharma Corporation. 1310 rue Nobel, Boucherville, Quebec, J4B 5H3, Canada Date of Authorization: July 13, 2018 Date of Revision: December 23, 2022 Submission Control Number: 265948 JAMP-Cholestyramine (Cholestyramine for Oral Suspension, USP) Page 2 of 27 RECENT MAJOR LABEL CHANGES TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ..................................................................................................................... 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS ..................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................. 5 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations ....................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .......... Preberite celoten dokument